Verona Pharma Plc ADR (NASDAQ: VRNA) is 42.15% higher on its value in year-to-date trading and has touched a low of $11.39 and a high of $30.73 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VRNA stock was last observed hovering at around $29.66 in the last trading session, with the day’s loss setting it -1.4%.
Currently trading at $28.26, the stock is -0.56% and 10.11% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.92 million and changing -4.72% at the moment leaves the stock 52.41% off its SMA200. VRNA registered 70.65% gain for a year compared to 6-month gain of 75.09%. The firm has a 50-day simple moving average (SMA 50) of $25.786 and a 200-day simple moving average (SMA200) of $18.61555.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 5.88% loss in the last 1 month and extending the period to 3 months gives it a 92.38%, and is -3.32% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.64% over the week and 5.70% over the month.
Verona Pharma Plc ADR (VRNA) has around 79 employees, a market worth around $2.29B and $0.00M in sales. Distance from 52-week low is 148.11% and -8.04% from its 52-week high. The company has generated returns on investments over the last 12 months (-32.54%).
Verona Pharma Plc ADR quarterly earnings per share for the current quarter are estimated at -0.5 with sales reaching $1.94M over the same period.The EPS is expected to shrink by -188.89% this year
170.0 institutions hold shares in Verona Pharma Plc ADR (VRNA), with institutional investors hold 94.79% of the company’s shares. The shares outstanding are 80.44M, and float is at 62.79M with Short Float at 14.09%. Institutions hold 91.80% of the Float.
The top institutional shareholder in the company is RA CAPITAL MANAGEMENT, L.P. with over 7.63 million shares valued at $110.37 million. The investor’s holdings represent 9.4566 of the VRNA Shares outstanding. As of 2024-06-30, the second largest holder is NEA MANAGEMENT COMPANY, LLC with 5.58 million shares valued at $80.76 million to account for 6.9193 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 4.0 million shares representing 4.9559 and valued at over $57.84 million, while VIVO CAPITAL, LLC holds 4.398 of the shares totaling 3.55 million with a market value of $51.33 million.
Verona Pharma Plc ADR (VRNA) Insider Activity
The most recent transaction is an insider sale by ZACCARDELLI DAVID, the company’s President and CEO. SEC filings show that ZACCARDELLI DAVID sold 600,000 shares of the company’s common stock on Sep 11 ’24 at a price of $3.76 per share for a total of $2.25 million. Following the sale, the insider now owns 15.25 million shares.
Verona Pharma Plc ADR disclosed in a document filed with the SEC on Sep 11 ’24 that Hahn Mark W (Chief Financial Officer) sold a total of 600,000 shares of the company’s common stock. The trade occurred on Sep 11 ’24 and was made at $3.76 per share for $2.25 million. Following the transaction, the insider now directly holds 14.34 million shares of the VRNA stock.
Still, SEC filings show that on Sep 11 ’24, MARK HAHN (Officer) Proposed Sale 75,000 shares at an average price of $28.04 for $2.1 million. The insider now directly holds shares of Verona Pharma Plc ADR (VRNA).
